We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Warns Healthcare Providers of Practice Saline Administered to Patients

FDA Warns Healthcare Providers of Practice Saline Administered to Patients

January 22, 2015

Non-sterile saline solution meant only for training purposes and not use in humans has found its way to healthcare facilities and been incorrectly administered to patients in at least seven states, where it’s been linked to at least one death and has prompted the FDA to urge clinics, hospitals and other healthcare providers to check their saline stock.

More than 40 patients have been known to have been administered Practi-0.9% sodium chloride solution, a simulated IV saline solution manufactured by San Diego-based Wallcur. Many adverse events have been linked with administration of the practice solution, including fever, chills, tremors, headache and at least one death, although it’s unknown if that death is directly related to the saline, the FDA said in a safety alert.

The adverse events have been reported in Florida, Georgia, Idaho, Louisiana, North Carolina, New York and Colorado, according to the FDA.

Wallcur has initiated a voluntary recall of its saline and the FDA is urging clinicians and staff to check any products for labels that say “Wallcur,” “Practi-products,” “For clinical simulation,” or “Not for use in human or animal patients,” according to the alert. Wholesalers, distributors and suppliers are also asked to check their stock.

It’s unclear how the practice solution was shipped to healthcare facilities. The FDA said that it is currently investigating.

Healthcare providers have struggled recently with an ongoing shortage of saline. The FDA has been working with manufacturers to increase supply, the agency said. Wallcur did not respond to a request for additional comment by press time.

See the FDA warning notice here: www.fdanews.com/01-15-2015-Saline-Safety-Warning.pdf. – Bryan Koenig

Drugs

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Deems Cardiosave Intra-Aortic Balloon Recall Class I

  • Xtandi Shows Promise in Prostate Cancer Trial

  • Implantable Sleeve that Holds Spinal Screws in Place Gets FDA Clearance

  • FDA Green Lights Clinical Trial of Low-Dose Psilocybin

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing